Stem Cell Therapeutics Corp. Announces the Publication of Key Animal Data to Support Efficacy of Its Stroke Regimen NTx(R)-265 i
May 28 2009 - 8:30AM
Marketwired
Stem Cell Therapeutics Corp. (TSX VENTURE: SSS) ("SCT" or "the
Company") announces the acceptance and publication of a paper
describing the effectiveness of the NTx�-265 stroke treatment
regimen when administered 24 hours after an ischemic stroke in
rats.
For the first time, this therapeutic strategy was shown to
improve behavioral outcome and reduced lesion volume with a time
window of 24 hours after the onset of stroke. These fundamental
results provided the evidence necessary to advance NTx�-265 into
the initial BETAS human stroke studies in acute ischemic
stroke.
Dr. Allen Davidoff, VP of Product Development commented as
follows:
"These exciting preclinical data formed the efficacy basis for
our move to the clinic, and it's encouraging to see publication of
these data in a quality, peer-reviewed journal."
The paper which is titled "A Novel Neurotrophic Therapeutic
Strategy for Experimental Stroke" will appear in the scientific
journal Brain Research (2009) and is currently available
online.
About Stem Cell Therapeutics Corp.: Stem Cell Therapeutics Corp.
is a Canadian public biotechnology company (TSX VENTURE: SSS)
focused on the development and commercialization of drug-based
therapies to treat central nervous system diseases. SCT is a leader
in the development of therapies that utilize drugs to stimulate a
patient's own resident stem cells. The Company's programs aim to
repair brain and nerve function lost due to disease or injury. The
Company's extensive patent portfolio of owned and licensed
intellectual property supports the potential expansion into future
clinical programs in numerous neurological diseases such as
traumatic brain injury, multiple sclerosis, Huntington's disease,
Alzheimer's disease, and ALS.
For further information on Stem Cell Therapeutics Corp., visit
www.stemcellthera.com.
These securities have not been registered under the United
States Securities Act of 1933, as amended, or the securities laws
of any state, and may not be offered or sold within the United
States or to, or for the account or benefit of U.S. persons unless
an applicable exemption from U.S. registration requirements is
available.
Except for historical information, this press release may
contain forward-looking statements, which reflect the Company's
current expectation regarding future events. These forward-looking
statements involve risk and uncertainties, which may cause but are
not limited to, changing market conditions, the successful and
timely completion of clinical studies, the establishment of
corporate alliances, the impact of competitive products and
pricing, new product development, uncertainties related to the
regulatory approval process and other risks detailed from time to
time in the Company's ongoing quarterly and annual reporting.
The TSX Venture Exchange does not accept responsibility for the
adequacy or accuracy of this release.
Contacts: Stem Cell Therapeutics Corp. Alan Moore, PhD President
and CEO 403-245-5495 ext.224 amoore@stemcellthera.com Stem Cell
Therapeutics Corp. Chloe Douglas-Crampton Investor Relations
403-245-5495 ext. 221 crampton@stemcellthera.com
www.stemcellthera.com
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sunvest Minerals Corp (TSXV:SSS)
Historical Stock Chart
From Jul 2023 to Jul 2024